Riskpilot← Back to searchSign inGet full accessNOVA BIOTICS AS
ASActiveOrg 981556267Undelstad Terrasse 25B, 1387 AskerManufacture of homogenised food preparations and dietetic food · NACE 1086Est. 20000 employees
Revenue 2024
NOK 36K
-12% vs 2023
EBITDA margin
2.7%
-87% vs 2023
Equity ratio
-12.7%
Financial strength
Net profit 2024
NOK 973
-87% vs 2023
| Revenue | NOK 36K | -12% |
| EBITDA | NOK 973 | -87% |
| Net profit | NOK 973 | -87% |
| Total assets | NOK 166K | +1% |
| Equity | NOK -21K | +4% |
| Employees | 0 | — |
Legal name
NOVA BIOTICS AS
Org number
981556267
Legal form
Aksjeselskap
NACE code
1086 · Manufacture of homogenised food preparations and dietetic food
Founded
1. mars 2000
Share capital
NOK 102 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i felleskap.
Company purpose
Produsere, markedsføre, selge og eksportere kosttilskudd, functional foods og legemidler i forskjellige distribusjonskanaler. Dessuten å delta og samarbeide med firma med liknende virksomhet.
Address
Undelstad Terrasse 25B, 1387 Asker
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 141 | 0 | 0 | 0 | 10 | 16 | 15 | 14 | 32 | 49 | 82 | 86 | 73 | 77 | 61 | 40 | 36 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −9 | −148 | −40 | −33 | −36 | −19 | −21 | −41 | −16 | 4 | 42 | 23 | 17 | 41 | 11 | 7 | 1 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −9 | −148 | −40 | −33 | −36 | −19 | −21 | −41 | −16 | 4 | 42 | 23 | 17 | 41 | 11 | 7 | 1 |
| Net financials | −6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −15 | −148 | −40 | −33 | −36 | −19 | −21 | −41 | −16 | 4 | 42 | 23 | 17 | 41 | 11 | 7 | 1 |
| Tax | −0 | −4 | −5 | −0 | −0 | 0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −15 | −144 | −35 | −33 | −36 | −19 | −21 | −41 | −16 | 4 | 42 | 23 | 17 | 41 | 11 | 7 | 1 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 191 | 48 | 14 | 21 | 10 | 10 | 19 | 28 | 19 | 23 | 114 | 90 | 107 | 148 | 159 | 164 | 166 |
| Equity | 178 | 34 | −1 | −33 | −70 | −89 | −110 | −151 | −167 | −163 | −121 | −98 | −81 | −40 | −30 | −22 | −21 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 13 | 14 | 14 | 54 | 80 | 99 | 129 | 179 | 186 | 186 | 235 | 188 | 188 | 188 | 189 | 187 | 187 |
| Total debt | 13 | 14 | 14 | 54 | 80 | 99 | 129 | 179 | 186 | 186 | 235 | 188 | 188 | 188 | 189 | 187 | 187 |
EBITDA margin
2.7%
This company
15.8%
Market median
-83% vs market
20082024
Equity ratio
-12.7%
This company
38.2%
Market median
-133% vs market
20082024
Return on equity
97300.0%
This company
18.4%
Market median
+528704% vs market
20082024
Net profit margin
2.7%
This company
8.1%
Market median
-67% vs market
20082024
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20082024
Debt / equity
8.89×
This company
0.62×
Market median
-1334% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JY Chief Executive Officer | Chief Executive Officer | 2000 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2007 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nova Biopharm As | Company | 49.0% | 49.0% | 2022 |
| Individual | 2.0% | 2.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nova Biopharm As
NOVA BIOTICS AS Board members of NOVA BIOTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Yngvar Piene | Chief Executive Officer | 0 companies |
| Jørn Gjessing | Chairman | 0 companies |